About This Tool

The Ulcerative Colitis Biologic Dosing Calculator is designed to assist healthcare professionals by providing standard dosing regimens for various advanced therapies used in the management of Ulcerative Colitis (UC). It interprets prescribing information for multiple agents to output phase-specific dosing schedules, including induction, maintenance, and potential dose optimization strategies. This tool should be used for informational purposes and not as a replacement for clinical judgment or official prescribing documents.

Outputs

After entering the required information, the calculator will generate a clear summary of the recommended dosing regimen. The output includes:

• Dose & Route: The specific dose (e.g., mg or mg/kg) and method of administration (e.g., IV infusion, subcutaneous injection, oral).
• Frequency: The dosing schedule for the selected treatment phase, such as the loading dose schedule for induction or the recurring interval for maintenance.
• TDM Notes: If therapeutic drug monitoring (TDM) data is entered for dose optimization, the tool provides context based on typical therapeutic targets.
• Safety Information: Quick access to summaries of key monitoring requirements and Black Box Warnings for the selected drug.

How to Use

To calculate a dosing regimen, follow these steps:

1. Select Therapy: Choose the desired biologic, JAK inhibitor, or S1P modulator from the dropdown menu.
2. Enter Patient Weight: If the selected drug requires weight-based dosing (e.g., Infliximab, Ustekinumab), input the patient's weight and select the appropriate unit (kg or lbs). This field will be hidden for drugs with fixed dosing.
3. Choose Treatment Phase: Select whether you are calculating for the initial 'Induction' phase, ongoing 'Maintenance', or 'Dose Optimization' due to loss of response.
4. (Optional) Enter TDM Levels: For the 'Dose Optimization' phase, you can enter trough and antibody levels to receive additional context on the calculated dosing strategy.
5. Calculate: Click the "Calculate" button to view the results.

Dosing Overview

Dosing for advanced therapies in Ulcerative Colitis typically involves two distinct phases:

• Induction Phase: A higher-dose or more frequent initial loading schedule designed to rapidly achieve therapeutic drug levels, gain control of inflammation, and induce a clinical response.
• Maintenance Phase: A lower-dose or less frequent ongoing schedule designed to maintain therapeutic levels, prevent disease flares, and sustain remission.

The administration method and dosing calculation vary by drug. For example, infliximab dosing is weight-based (mg/kg) and administered via IV infusion, while adalimumab uses a fixed-dose subcutaneous injection schedule.

Switching Therapies

When a patient loses response to one therapy or experiences intolerable side effects, switching to a different agent may be necessary. The decision to switch should be based on a thorough evaluation, including assessing disease activity, drug levels, and anti-drug antibodies. There is no universal standard for washout periods when switching; this decision depends on the drug's mechanism of action and half-life. Generally, the induction dose of the new medication is started at the time the next dose of the old medication would have been due.

Missed Dose

Guidance for a missed dose varies by medication. Always consult the specific drug's prescribing information. As a general guide:

• For frequent subcutaneous injections (e.g., every 1-2 weeks): The patient should typically take the dose as soon as they remember and then resume their original schedule.
• For less frequent IV infusions or injections (e.g., every 4-8 weeks): The patient should contact their healthcare provider or infusion center to reschedule the dose as soon as possible.

Safety Alerts

All advanced therapies for Ulcerative Colitis carry potential risks. It is crucial to be aware of the specific warnings and precautions for each agent. Common safety concerns across different drug classes include:

• Serious Infections: Most of these therapies suppress the immune system, increasing the risk of bacterial, fungal, and viral infections. Screening for latent tuberculosis (TB) and hepatitis B is mandatory before starting many of these agents.
• Malignancy: Some therapies, particularly TNF inhibitors and JAK inhibitors, carry an increased risk of certain cancers, such as lymphoma and skin cancer.
• Class-Specific Risks: JAK inhibitors have Black Box Warnings for major adverse cardiovascular events (MACE) and thrombosis. S1P modulators require dose titration to mitigate cardiac effects and have specific contraindications.

Frequently Asked Questions

Why is weight required for Infliximab but not for Adalimumab?

Infliximab's approved dosing is based on the patient's body weight (mg/kg) to ensure adequate drug exposure. Adalimumab, along with many other biologics, has been studied and approved with a fixed-dose regimen that is effective for the majority of the adult population, simplifying administration.

What do the optional Trough and Antibody Level inputs mean?

These inputs are for Therapeutic Drug Monitoring (TDM). The 'Trough Level' is the concentration of the drug in the blood right before the next dose is due. The 'Antibody Level' measures anti-drug antibodies that can neutralize the drug and lead to treatment failure. This information helps determine if a loss of response is due to low drug levels (requiring a dose increase) or high antibody levels (suggesting a switch in therapy).

Does this calculator account for pediatric patients or renal/hepatic impairment?

No. This tool is intended for adult dosing based on standard prescribing information. It does not provide adjustments for pediatric populations, renal or hepatic impairment, or other special populations. Always consult the full prescribing information for specific guidance.

Can this calculator be used for Crohn's Disease?

No. While many of these drugs are also approved for Crohn's Disease, the dosing regimens can differ significantly. This calculator is validated only for Ulcerative Colitis dosing.

What is the difference between the IV and SQ options for Vedolizumab maintenance?

After completing the IV induction series, patients have the option to continue with IV infusions every 8 weeks or switch to a subcutaneous (SQ) injection every 2 weeks. The calculator provides information on both approved maintenance pathways.

Why does Ozanimod require a 7-day dose titration?

Ozanimod is an S1P receptor modulator that can cause a temporary decrease in heart rate when first started. The gradual dose titration over 7 days is a required safety measure to mitigate this potential cardiac effect and allow the body to acclimate to the medication.

What should I do if a patient loses response on a maintenance dose?

Select the 'Dose Optimization' phase in the calculator. This will show common strategies for recapturing response, which may include increasing the dose or shortening the dosing interval. Therapeutic drug monitoring can be highly valuable in guiding this decision.

Where does the dosing information in this calculator come from?

All dosing information is derived from the U.S. Food and Drug Administration (FDA) approved prescribing information for each medication. It is periodically reviewed for accuracy but users should always verify with the most current official labels.

References

1. Drugs@FDA Database - U.S. Food and Drug Administration
2. Medicines Database - European Medicines Agency
3. Rubin DT, Ananthakrishnan AN, Siegel CA, Sauer BG, Long MD. ACG Clinical Guideline: Ulcerative Colitis in Adults. Am J Gastroenterol. 2019;114(3):384-413.
4. REMICADE® (infliximab) Prescribing Information. Janssen Biotech, Inc.
5. ENTYVIO® (vedolizumab) Prescribing Information. Takeda Pharmaceuticals.
6. RINVOQ® (upadacitinib) Prescribing Information. AbbVie Inc.